JP4732696B2 - 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 - Google Patents
活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 Download PDFInfo
- Publication number
- JP4732696B2 JP4732696B2 JP2003581758A JP2003581758A JP4732696B2 JP 4732696 B2 JP4732696 B2 JP 4732696B2 JP 2003581758 A JP2003581758 A JP 2003581758A JP 2003581758 A JP2003581758 A JP 2003581758A JP 4732696 B2 JP4732696 B2 JP 4732696B2
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- active ingredient
- microcapsules
- suspension according
- liquid phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204409 | 2002-04-09 | ||
FR02/04409 | 2002-04-09 | ||
FR02/10847 | 2002-09-02 | ||
FR0210847A FR2843881B1 (fr) | 2002-09-02 | 2002-09-02 | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
PCT/FR2003/001096 WO2003084518A2 (fr) | 2002-04-09 | 2003-04-07 | Suspension orale de microcapsules de principes actifs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005527573A JP2005527573A (ja) | 2005-09-15 |
JP2005527573A5 JP2005527573A5 (pt) | 2006-06-01 |
JP4732696B2 true JP4732696B2 (ja) | 2011-07-27 |
Family
ID=28793279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003581758A Expired - Lifetime JP4732696B2 (ja) | 2002-04-09 | 2003-04-07 | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 |
Country Status (16)
Country | Link |
---|---|
US (5) | US7906145B2 (pt) |
EP (1) | EP1492511B3 (pt) |
JP (1) | JP4732696B2 (pt) |
KR (1) | KR101061351B1 (pt) |
CN (1) | CN100553625C (pt) |
AT (1) | ATE419840T1 (pt) |
AU (1) | AU2003246792B2 (pt) |
BR (1) | BRPI0309142C1 (pt) |
CA (1) | CA2480826C (pt) |
DE (1) | DE60325709D1 (pt) |
ES (1) | ES2320438T7 (pt) |
HK (1) | HK1079448A1 (pt) |
IL (2) | IL164222A0 (pt) |
MX (1) | MXPA04009968A (pt) |
PT (1) | PT1492511E (pt) |
WO (1) | WO2003084518A2 (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
MXPA04009968A (es) | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
FR2841140B1 (fr) * | 2002-06-24 | 2004-10-01 | Servier Lab | Microcapsules pour la liberation retardee et controlee du perindopril |
FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
FR2842735B1 (fr) * | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
FR2881652B1 (fr) * | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
FR2889810A1 (fr) * | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
FR2884145A1 (fr) * | 2005-04-06 | 2006-10-13 | Flamel Technologies Sa | Forme pharmaceutique orale de losartan |
US20090123536A1 (en) * | 2005-02-21 | 2009-05-14 | Flamel Technologies, S.A. | Oral Pharmaceutical Form of Losartan |
FR2882260A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii |
FR2882259A1 (fr) * | 2005-02-21 | 2006-08-25 | Flamel Technologies Sa | Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan |
GB0507167D0 (en) | 2005-04-08 | 2005-05-18 | Glaxosmithkline Consumer Healt | Composition |
WO2006122022A2 (en) * | 2005-05-10 | 2006-11-16 | Novartis Ag | Modified release famciclovir pharmaceutical compositions |
WO2007022105A2 (en) * | 2005-08-12 | 2007-02-22 | Rubicon Research Pvt. Ltd. | Stable pharmaceutical compositions, processes for making the same, and methods of their use |
DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
KR101765357B1 (ko) * | 2009-12-02 | 2017-08-04 | 아데어 파마수티컬스 에스.알.엘. | 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물 |
WO2011077451A2 (en) * | 2009-12-22 | 2011-06-30 | Abbott Healthcare Private Limited | Controlled release pharmaceutical composition |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
US9254281B2 (en) * | 2011-09-12 | 2016-02-09 | Wright State University | Composition and method for the treatment of neurodegeneration |
CN102579398A (zh) * | 2011-12-31 | 2012-07-18 | 沈阳药科大学 | 一种具有掩盖药物不良口味作用的肠溶微囊及制备方法 |
CN102552163B (zh) * | 2012-01-05 | 2013-12-04 | 金陵药业股份有限公司 | 一种酒石酸美托洛尔缓释微丸及其制备方法 |
BR112015003120B1 (pt) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
ES2758515T3 (es) | 2013-03-12 | 2020-05-05 | Panacea Biomatx Inc | Sistema para hacer formulaciones personalizadas para los individuos |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US20180104197A9 (en) * | 2014-05-01 | 2018-04-19 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of metformin |
US10258583B2 (en) | 2014-05-01 | 2019-04-16 | Sun Pharmaceutical Industries Limited | Extended release liquid compositions of guanfacine |
WO2015166473A1 (en) | 2014-05-01 | 2015-11-05 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
RU2016147008A (ru) * | 2014-05-01 | 2018-06-04 | Сан Фармасьютикал Индастриз Лимитед | Жидкие композиции метформина с пролонгированным высвобождением |
JP6335692B2 (ja) * | 2014-07-08 | 2018-05-30 | ライオン株式会社 | 液体経口製剤 |
US10285908B2 (en) | 2014-07-30 | 2019-05-14 | Sun Pharmaceutical Industries Ltd | Dual-chamber pack |
KR20170044667A (ko) * | 2014-08-15 | 2017-04-25 | 다우 글로벌 테크놀로지스 엘엘씨 | 에틸셀룰로오스 분산물 및 분말 |
MA41124A (fr) * | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
US9757394B2 (en) * | 2015-10-30 | 2017-09-12 | Cmp Development Llc | Spironolactone aqueous formulations |
US10493083B2 (en) | 2015-10-30 | 2019-12-03 | Cmp Development Llc | Spironolactone aqueous compositions |
US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
EP3445356B1 (en) | 2016-04-22 | 2021-06-30 | Receptor Holdings, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
US10238803B2 (en) | 2016-05-02 | 2019-03-26 | Sun Pharmaceutical Industries Limited | Drug delivery device for pharmaceutical compositions |
US10369078B2 (en) | 2016-05-02 | 2019-08-06 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for pharmaceutical compositions |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
GB201716716D0 (en) | 2017-10-12 | 2017-11-29 | Univ Of Hertfordshire Higher Education Corporation | Method for coating particles |
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
WO2019126218A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release |
US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
WO2020011938A1 (en) | 2018-07-11 | 2020-01-16 | Medizinische Universität Wien | Glucocorticoids for the topical treatment of autoimmune gastritis |
EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
US20220133647A1 (en) * | 2019-03-01 | 2022-05-05 | Avadel Legacy Pharmaceuticals, Llc | Liquid guaifenesin compositions with stable extended release profiles |
CN115243568B (zh) * | 2019-09-12 | 2023-10-17 | 努利希尔有限公司 | 受控释放的核-壳粒子及包含其的悬浮液 |
CN112370437B (zh) * | 2020-10-20 | 2022-10-21 | 好医生药业集团有限公司 | 一种阿莫西林胶囊及其制备方法 |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (288)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029884A (en) | 1971-03-18 | 1977-06-14 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
CA1019727A (en) | 1971-03-18 | 1977-10-25 | Abbott Laboratories | Adenosine-5'-carboxylic acid amides |
US3927216A (en) | 1971-06-01 | 1975-12-16 | Icn Pharmaceuticals | 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections |
US3864483A (en) | 1972-03-22 | 1975-02-04 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US3914414A (en) | 1973-06-14 | 1975-10-21 | Abbott Lab | Method of increasing coronary pO{HD 2 {B in mammals |
US3914415A (en) | 1973-06-14 | 1975-10-21 | Abbott Lab | Adenosine-5{40 -carboxylic acid amides |
US3892769A (en) | 1973-07-20 | 1975-07-01 | Merck & Co Inc | Acetaminophen esters of aryl salicylic acids |
US3980766A (en) | 1973-08-13 | 1976-09-14 | West Laboratories, Inc. | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
DE2417465A1 (de) | 1974-04-10 | 1975-10-30 | Lester R Wellman | Vorrichtung zum oeffnen und wiederverschliessen eines dicht verschlossenen flexiblen behaelters |
US3966917A (en) | 1974-07-30 | 1976-06-29 | Abbott Laboratories | Platelet aggregation inhibitors |
DE2530563C2 (de) | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
FR2313915A1 (fr) | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US4308251A (en) | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
JPS6056122B2 (ja) | 1980-05-21 | 1985-12-09 | 塩野義製薬株式会社 | 徐放性製剤 |
US4321253A (en) | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
US4454309A (en) | 1980-11-12 | 1984-06-12 | Tyndale Plains-Hunter, Ltd. | Polyurethane polyene compositions |
JPS57197214A (en) | 1981-05-29 | 1982-12-03 | Tanabe Seiyaku Co Ltd | Rapid-releasing microcapsule and its preparation |
US4443549A (en) | 1981-10-19 | 1984-04-17 | Molecular Genetics, Inc. | Production of monoclonal antibodies against bacterial adhesins |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4507276A (en) | 1982-08-20 | 1985-03-26 | Bristol-Myers Company | Analgesic capsule |
US4461759A (en) | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
US4833905A (en) | 1983-06-03 | 1989-05-30 | Micromatic Textron Inc. | Method for splining clutch hubs with close tolerance spline bellmouth and oil seal surface roundness |
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
EP0179023B1 (fr) | 1984-10-19 | 1991-01-23 | Battelle Memorial Institute | Polypeptide biodégradable et son utilisation pour le relargage progressif de médicaments |
EP0198769A3 (en) | 1985-04-12 | 1987-09-02 | Forest Laboratories, Inc. | Floating sustained release therapeutic compositions |
EP0202027A1 (en) | 1985-04-18 | 1986-11-20 | Sumitomo Chemical Company, Limited | A herbicidal composition |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
LU85943A1 (fr) | 1985-06-12 | 1987-01-13 | Galephar | Comprimes pharmaceutiques permettant l'administration aisee de pellets, leur preparation et leur utilisation |
IT1185177B (it) * | 1985-07-03 | 1987-11-04 | Metalvuoto Films Spa | Dispositivo per realizzare film plastici metallizzati presentanti zone ben delimitate prive di metallizzazione |
US5002551A (en) | 1985-08-22 | 1991-03-26 | Johnson & Johnson Medical, Inc. | Method and material for prevention of surgical adhesions |
US4693896A (en) | 1985-10-07 | 1987-09-15 | Fmc Corporation | Ethylcellulose-coated, gastric-disintegrable aspirin tablet |
DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
AU591248B2 (en) | 1986-03-27 | 1989-11-30 | Kinaform Technology, Inc. | Sustained-release pharaceutical preparation |
SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
IT1200217B (it) | 1986-09-30 | 1989-01-05 | Valducci Roberto | Membrana per uso farmaceutico ed industriale |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
SE8605515D0 (sv) | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A liquid dosage form for oral administration of a pharmaceutically active substance |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
ES2061623T3 (es) | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US4902513A (en) * | 1987-07-31 | 1990-02-20 | Jean Carvais | Oral sustained release medicament |
US4837031A (en) | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
US4961932A (en) | 1987-10-26 | 1990-10-09 | Alza Corporation | Plurality of tiny pills in liquid dosage form |
DE3810757A1 (de) | 1988-03-30 | 1989-10-26 | Freudenberg Carl Fa | Verfahren zur herstellung einer mikroporoesen folie |
US5268182A (en) | 1988-06-24 | 1993-12-07 | Abbott Laboratories | Sustained-release drug dosage units of terazosin |
FR2634377B1 (fr) | 1988-06-30 | 1991-09-27 | Cortial | Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif |
US5028434A (en) | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
IT1226940B (it) | 1988-09-16 | 1991-02-22 | Recordati Chem Pharm | Sistema terapeutico a rilascio controllato per formulazioni farmaceutiche liquide |
FI894611A (fi) | 1988-09-30 | 1990-03-31 | May & Baker Ltd | Granulaera farmaceutiska preparat. |
US5186930A (en) * | 1988-11-14 | 1993-02-16 | Schering Corporation | Sustained release oral suspensions |
US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
IT1227899B (it) * | 1988-12-23 | 1991-05-14 | Poli Ind Chimica Spa | Rivestimento totale o parziale di principi attivi farmaceutici e relative composizioni |
CA2007181C (en) | 1989-01-06 | 1998-11-24 | Angelo Mario Morella | Sustained release pharmaceutical composition |
FR2642080B1 (fr) | 1989-01-23 | 1992-10-02 | Onera (Off Nat Aerospatiale) | Polysilanes et leur procede de preparation |
US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
US5026559A (en) | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5084278A (en) | 1989-06-02 | 1992-01-28 | Nortec Development Associates, Inc. | Taste-masked pharmaceutical compositions |
AU632602B2 (en) | 1989-08-02 | 1993-01-07 | John David Arnold | Method and preparation for reducing risk of myocardial infarction |
NZ233975A (en) | 1989-08-16 | 1992-06-25 | Sterling Drug Inc | Aspirin granules coated with a gastroprotectant |
IT1256651B (it) | 1992-12-11 | 1995-12-12 | Giancarlo Santus | Composizione farmaceutica a rilascio controllato in sospensione liquida |
CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
EP0499619B1 (en) | 1989-11-06 | 1996-02-07 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5248516A (en) | 1989-12-19 | 1993-09-28 | Fmc Corporation | Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like |
GB9002495D0 (en) | 1990-02-05 | 1990-04-04 | Monsanto Europe Sa | Glyphosate compositions |
US5206030A (en) | 1990-02-26 | 1993-04-27 | Fmc Corporation | Film-forming composition and use for coating pharmaceuticals, foods and the like |
IT1246383B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
WO1991019486A1 (en) | 1990-06-14 | 1991-12-26 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
JP3049367B2 (ja) | 1990-06-20 | 2000-06-05 | アストラゼネカ・アクチエボラーグ | ジアルコキシ−ピリジニル−ベンズイミダゾール誘導体、その製造方法およびそれを含む医薬 |
WO1992001446A1 (en) | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
SE9002684D0 (sv) | 1990-08-17 | 1990-08-17 | Malvac Foundation C O Peter Pe | New peptides and their use |
EP0477135A1 (en) | 1990-09-07 | 1992-03-25 | Warner-Lambert Company | Chewable spheroidal coated microcapsules and methods for preparing same |
GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5219895A (en) | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5431922A (en) | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
FI922107A0 (fi) | 1991-05-10 | 1992-05-08 | Faulding F H & Co Ltd | Mikrokapselkomposition och foerfarande. |
US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
DE69220317T2 (de) | 1991-10-01 | 1997-10-16 | Takeda Chemical Industries Ltd | Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5409709A (en) | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
DE4200821A1 (de) * | 1992-01-15 | 1993-07-22 | Bayer Ag | Geschmacksmaskierte pharmazeutische mittel |
US5571533A (en) | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
US5286495A (en) | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
IL103224A (en) | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
CA2147862A1 (en) | 1992-11-05 | 1994-05-11 | Robert E. Dempski | Drug delivery device |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
FR2708932B1 (fr) | 1993-08-10 | 1995-11-10 | Flamel Tech Sa | Procédé de préparation de polyaminoacides. |
HU218673B (hu) | 1993-10-07 | 2000-10-28 | Euroceltique S.A. | Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására |
GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
IT1269578B (it) * | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
CN1096862C (zh) | 1994-05-06 | 2002-12-25 | 辉瑞大药厂 | 阿齐霉素的控释剂型 |
IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
JPH0873345A (ja) | 1994-09-05 | 1996-03-19 | Terumo Corp | 医薬製剤 |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
FR2724563A1 (fr) | 1994-09-15 | 1996-03-22 | Coletica | Utilisation de membranes collageniques comme protheses de regeneration peritoneale |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5858398A (en) | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
GB9423588D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
KR0167613B1 (ko) | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | 사이클로스포린-함유 연질캅셀제 조성물 |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
JP2690276B2 (ja) | 1995-01-10 | 1997-12-10 | 科学技術振興事業団 | 静電結合型高分子ミセル薬物担体とその薬剤 |
FR2732218B1 (fr) | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
US5750468A (en) | 1995-04-10 | 1998-05-12 | Monsanto Company | Glyphosate formulations containing etheramine surfactants |
US5674529A (en) | 1995-06-06 | 1997-10-07 | Church & Dwight Co., Inc. | Alkalinizing potassium salt controlled release preparations |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
HUP9901437A3 (en) | 1995-09-07 | 2000-03-28 | Smithkline Beecham Plc | Pharmaceutical formulation, containing amoxycillin and clavulanate |
DE69636413T2 (de) | 1995-11-13 | 2007-03-29 | North West University | Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
JP2000501736A (ja) | 1995-12-12 | 2000-02-15 | メルク エンド カンパニー インコーポレーテッド | ロサルタンの新用途 |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
FR2746035B1 (fr) | 1996-03-15 | 1998-06-12 | Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications | |
US20030064108A1 (en) | 1996-04-23 | 2003-04-03 | Stefan Lukas | Taste masked pharmaceutical compositions |
DE19628341C2 (de) * | 1996-07-13 | 1998-09-17 | Sihl Gmbh | Aufzeichnungsmaterial für Tintenstrahlverfahren mit wäßriger Tinte und Verwendung zum Herstellen wasserfester und lichtbeständiger Aufzeichnungen auf diesem Material |
FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
US5780055A (en) | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
AU5101798A (en) | 1996-12-04 | 1998-06-29 | Bristol-Myers Squibb Company | Method for oral administration of buspirone |
EP0953359A4 (en) | 1996-12-19 | 2001-12-19 | Daiichi Seiyaku Co | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION |
FR2759083B1 (fr) | 1997-02-06 | 1999-04-30 | Dev Des Utilisations Du Collag | Materiau collagenique utile notamment pour la prevention d'adherences post-operatoires |
US5981761A (en) | 1997-03-27 | 1999-11-09 | Solutia Inc. | Crosslinked polyaspartate salts a process for their production |
US6162463A (en) | 1997-05-01 | 2000-12-19 | Dov Pharmaceutical Inc | Extended release formulation of diltiazem hydrochloride |
AU733912B2 (en) | 1997-05-30 | 2001-05-31 | Monsanto Company | Process and compositions promoting biological effectiveness of exogenous chemical substances in plants |
WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
JP3677156B2 (ja) | 1997-09-05 | 2005-07-27 | 武田薬品工業株式会社 | 医薬 |
US6692767B2 (en) | 1997-09-19 | 2004-02-17 | Shire Laboratories Inc. | Solid solution beadlet |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
FR2771291B1 (fr) | 1997-11-21 | 2000-02-25 | Ethypharm Lab Prod Ethiques | Spheroides, procede de preparation et compositions pharmaceutiques |
US6444246B1 (en) | 1997-12-16 | 2002-09-03 | Mccormick & Company, Inc. | Cake-resistant, hygroscopically sensitive materials and process for producing the same |
JP2001526229A (ja) | 1997-12-22 | 2001-12-18 | ユーロ−セルティーク,エス.エイ. | オピオイド投薬剤形の乱用を防止する方法 |
SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
EA003101B1 (ru) | 1998-03-19 | 2002-12-26 | Бристол-Майерз Сквибб Компани | Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
KR20010041019A (ko) | 1998-03-20 | 2001-05-15 | 요시히로 미와 | 위 및/또는 십이지장 부착성 의약 조성물 |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
IL162023A0 (en) | 1998-03-30 | 2005-11-20 | Rtp Pharma Inc | Compositions containing microparticles of water-insoluble substances and method for their preparation |
US5945123A (en) | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
ATE250418T1 (de) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
CN1163223C (zh) | 1998-07-28 | 2004-08-25 | 田边制药株式会社 | 肠内目标部位释放型制剂 |
US6179862B1 (en) | 1998-08-14 | 2001-01-30 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
JP2002525311A (ja) | 1998-10-01 | 2002-08-13 | エラン ファーマ インターナショナル,リミティド | 徐放性ナノ粒子組成物 |
JP2000128774A (ja) | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | 薬物を含有する球形微粒子の製法 |
CZ303495B6 (cs) | 1998-11-02 | 2012-10-24 | Elan Pharma International Limited | Mnohocásticový modifikovane uvolnující prostredek a jeho použití, pevná orální dávkovací forma |
EA007610B1 (ru) | 1998-11-12 | 2006-12-29 | Смитклайн Бичам Плс | Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение |
FR2786098B1 (fr) | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
DE19860698A1 (de) | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
DE60006362T2 (de) | 1999-02-23 | 2004-08-26 | Yuhan Corp. | Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
BE1013309A5 (fr) | 1999-04-13 | 2001-11-06 | Beecham Pharm Pte Ltd | Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium. |
US7576131B2 (en) | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
SE9902386D0 (sv) | 1999-06-22 | 1999-06-22 | Astra Ab | New formulation |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
JP2003522127A (ja) | 1999-07-29 | 2003-07-22 | ロクセニ ラボラトリーズ インコーポレイテッド | オピオイド徐放性製剤 |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
IL148411A0 (en) * | 1999-08-31 | 2002-09-12 | Gruenenthal Chemie | Delayed-action form of administration containing tramadol saccharinate |
DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
US6264983B1 (en) | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
AR028299A1 (es) | 1999-09-17 | 2003-05-07 | Novartis Ag | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. |
CA2389928C (en) | 1999-11-03 | 2010-03-23 | Bristol-Myers Squibb Company | Method for treating diabetes |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
FR2801226B1 (fr) | 1999-11-23 | 2002-01-25 | Flamel Tech Sa | Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation |
DE19961897A1 (de) * | 1999-12-20 | 2001-06-28 | Basf Ag | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
US7785625B2 (en) | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
WO2001058424A1 (en) | 2000-02-09 | 2001-08-16 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Floating drug delivery composition |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6951534B2 (en) | 2000-06-13 | 2005-10-04 | Acorn Cardiovascular, Inc. | Cardiac support device |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
JP2002003366A (ja) | 2000-06-23 | 2002-01-09 | Freunt Ind Co Ltd | 固形薬剤用水系コーティング剤組成物 |
BR0112124B1 (pt) | 2000-07-05 | 2011-06-14 | pà de celulose, processo para produzir um pà de celulose, excipiente, e, produto moldado. | |
FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
US7074417B2 (en) | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US6499158B1 (en) | 2000-10-30 | 2002-12-31 | Steris, Inc. | Surgical table top and accessory clamp used thereon |
FR2816840B1 (fr) | 2000-11-17 | 2004-04-09 | Flamel Tech Sa | Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation |
WO2002053097A2 (en) | 2000-12-28 | 2002-07-11 | Tap Pharmaceutical Products Inc. | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
JP2004525897A (ja) | 2001-02-14 | 2004-08-26 | グラクソ、ウェルカム、ソシエダッド、アノニマ | 医薬処方 |
JP2004520420A (ja) * | 2001-03-05 | 2004-07-08 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 味が遮蔽された製薬学的組成物 |
FR2821745B1 (fr) | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Granules et granules enrobes au gout masque |
BR0102252B1 (pt) | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
JP2004530676A (ja) | 2001-04-18 | 2004-10-07 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | 持続放出性薬学的組成物のための新規コーティング |
FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
GB0114532D0 (en) | 2001-06-14 | 2001-08-08 | Jagotec Ag | Novel compositions |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
WO2003013479A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
US7332182B2 (en) | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
CA2455420A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions and methods to prevent abuse of opioids |
WO2003013467A1 (de) | 2001-08-10 | 2003-02-20 | Beiersdorf Ag | Kosmetische reinigungsrezepturen auf basis einer kombination von natriumlaurethsulfat und alkylpolyamphopolycarboxyglycinaten |
US20030083286A1 (en) | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US6669955B2 (en) | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
EP1429728A1 (en) * | 2001-08-29 | 2004-06-23 | SRL Technologies, Inc. | Sustained release preparations |
US20030050620A1 (en) | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (fr) | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
GB0124459D0 (en) | 2001-10-11 | 2001-12-05 | Novartis Ag | Organic compounds |
US7413751B2 (en) | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US20030104052A1 (en) | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20040126428A1 (en) | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
FR2837100B1 (fr) | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
CA2479259A1 (en) | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent |
EP1490029A4 (en) | 2002-03-22 | 2006-02-22 | Ranbaxy Lab Ltd | DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN |
PT1578350E (pt) | 2002-03-26 | 2009-08-27 | Euro Celtique Sa | Composições revestidas com geles de libertação constante |
IL164221A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim |
MXPA04009968A (es) | 2002-04-09 | 2004-12-13 | Flamel Tech Sa | Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s). |
US20050106249A1 (en) | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
AU2003219184A1 (en) | 2002-05-09 | 2003-11-11 | Diffucap-Chemobras Quimica E Farmaceutica, Ltda. | Novel method of preparing programmed-release compositions containing (s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline and the product thus obtained |
AU2003229005A1 (en) | 2002-05-10 | 2003-11-11 | Merck And Co., Inc. | Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events |
NZ536693A (en) | 2002-05-31 | 2007-01-26 | Alza Corp | Controlled release dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
FR2840614B1 (fr) | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
NZ520149A (en) | 2002-07-12 | 2003-01-31 | Reinforced Concrete Pipes Pty | Anchoring device |
US20040208936A1 (en) | 2002-07-22 | 2004-10-21 | Roland Chorin | Novel compositions |
FR2842736B1 (fr) * | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
FR2843117B1 (fr) | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques |
US6727839B2 (en) | 2002-08-23 | 2004-04-27 | Broadcom Corporation | High speed, low power comparator |
US7538094B2 (en) | 2002-09-19 | 2009-05-26 | Three Rivers Pharmacueticals, Llc | Composition containing ribavirin and use thereof |
CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
JP2006510655A (ja) | 2002-12-11 | 2006-03-30 | ファイザー・プロダクツ・インク | 高脂肪環境への活性物質の制御放出 |
JP2004188307A (ja) | 2002-12-11 | 2004-07-08 | Japan Atom Energy Res Inst | リン酸基を有するジルコニウム担持繊維状吸着材の合成方法、及びそれを用いたヒ素の除去 |
AU2003299659A1 (en) | 2002-12-13 | 2004-07-09 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
EP1572164A2 (en) | 2002-12-18 | 2005-09-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
CA2513729A1 (en) | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
JP2006522099A (ja) | 2003-04-04 | 2006-09-28 | ファルマシア コーポレーション | 複合粒状体からなる経口徐放性圧縮錠 |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
JP5296314B2 (ja) | 2003-07-17 | 2013-09-25 | バナー ファーマキャップス,インコーポレイティド | 制御放出製剤 |
MXPA06001452A (es) | 2003-08-06 | 2007-04-02 | Gruenenthal Chemie | Forma de administracion a prueba de abuso. |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
CA2535451A1 (en) | 2003-08-13 | 2005-02-24 | Howard J. Smith & Associates Pty Ltd. | Method of treating viral infections |
US7470435B2 (en) | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
WO2005123039A1 (en) | 2004-06-12 | 2005-12-29 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
PL1786403T3 (pl) | 2004-07-01 | 2013-10-31 | Gruenenthal Gmbh | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
ATE413165T1 (de) | 2004-09-27 | 2008-11-15 | Sigmoid Pharma Ltd | Mikrokapseln mit einem methylxanthin und einem kortikosteroid |
CA2581002C (en) | 2004-10-15 | 2012-01-10 | Supernus Pharmaceuticals, Inc. | Less abusable pharmaceutical preparations |
FR2878161B1 (fr) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
FR2878158B1 (fr) | 2004-11-24 | 2009-01-16 | Flamel Technologies Sa | Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage |
FR2889810A1 (fr) | 2005-05-24 | 2007-02-23 | Flamel Technologies Sa | Forme medicamenteuse orale, microparticulaire, anti-mesurage |
FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
US20070166378A1 (en) * | 2005-06-09 | 2007-07-19 | Flamel Technologies, Inc. | Oral ribavirin pharmaceutical compositions |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
FR2892937B1 (fr) | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
-
2003
- 2003-04-07 MX MXPA04009968A patent/MXPA04009968A/es active IP Right Grant
- 2003-04-07 BR BRPI0309142A patent/BRPI0309142C1/pt not_active IP Right Cessation
- 2003-04-07 PT PT03745832T patent/PT1492511E/pt unknown
- 2003-04-07 ES ES03745832T patent/ES2320438T7/es active Active
- 2003-04-07 US US10/510,643 patent/US7906145B2/en active Active
- 2003-04-07 EP EP03745832A patent/EP1492511B3/fr not_active Expired - Lifetime
- 2003-04-07 DE DE60325709T patent/DE60325709D1/de not_active Expired - Lifetime
- 2003-04-07 JP JP2003581758A patent/JP4732696B2/ja not_active Expired - Lifetime
- 2003-04-07 WO PCT/FR2003/001096 patent/WO2003084518A2/fr active Application Filing
- 2003-04-07 CA CA2480826A patent/CA2480826C/fr not_active Expired - Lifetime
- 2003-04-07 IL IL16422203A patent/IL164222A0/xx unknown
- 2003-04-07 KR KR1020047016079A patent/KR101061351B1/ko active IP Right Grant
- 2003-04-07 CN CNB038105284A patent/CN100553625C/zh not_active Expired - Lifetime
- 2003-04-07 AU AU2003246792A patent/AU2003246792B2/en not_active Expired
- 2003-04-07 AT AT03745832T patent/ATE419840T1/de active
-
2004
- 2004-09-22 IL IL164222A patent/IL164222A/en active IP Right Grant
-
2005
- 2005-12-17 HK HK05111660.1A patent/HK1079448A1/xx not_active IP Right Cessation
-
2011
- 2011-01-26 US US13/014,137 patent/US10004693B2/en not_active Expired - Lifetime
-
2015
- 2015-09-09 US US14/848,603 patent/US20150374635A1/en not_active Abandoned
- 2015-09-09 US US14/848,699 patent/US9814684B2/en not_active Expired - Lifetime
-
2017
- 2017-06-16 US US15/625,727 patent/US20170281558A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4732696B2 (ja) | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 | |
JP4698950B2 (ja) | アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 | |
JP4991072B2 (ja) | 時限拍動性薬物送達システム | |
JP5430815B2 (ja) | 低溶解性活性成分の延長された放出のための、複数のマイクロカプセルの形体である経口医薬品製剤 | |
US5670172A (en) | Pharmaceutical spheroid formulation | |
JP2005535680A (ja) | 経口送達のための、低溶解性活性成分の放出が改変されたマイクロカプセル | |
JP2005527522A (ja) | マイクロカプセルをベースとした徐放性錠剤 | |
CZ303495B6 (cs) | Mnohocásticový modifikovane uvolnující prostredek a jeho použití, pevná orální dávkovací forma | |
JP2005506336A (ja) | 薬学的活性成分の遅延かつ制御された放出のための微小粒子経口ガレヌス製剤形態 | |
JP3645816B2 (ja) | ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物 | |
EP1581197A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
ZA200407594B (en) | Oral suspension of active principle microcapsules | |
BR122013000700B1 (pt) | "suspension microcapsules in a net stage aquasa" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20060406 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100401 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100506 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110322 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110421 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4732696 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |